7
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T2753 |
Avasimibe
PD-148515,阿伐麦布,CI-1011 |
P450; Acyltransferase | Metabolism |
Avasimibe (PD-148515) 是一种口服有效的酰基辅酶 A: 胆固醇酰基转移酶 (ACAT) 抑制剂,对 ACAT1和 ACAT2的 IC50分别为 24 和 9.2 µM。Avasimibe 在前列腺癌中有研究的价值。 | |||
T31611 |
Eldacimibe
WAY-ACA-147,UNII-4PBL76O2G8,ANA 147,ACA 147 |
Acyltransferase | Metabolism |
Eldacimibe (WAY-ACA-147) 是一种ACAT2抑制剂,可用于治疗心血管疾病和内分泌与代谢疾病,研究动脉粥样硬化和高胆固醇血症。 | |||
T12225L |
Nevanimibe hydrochloride
PD-132301 hydrochloride,ATR101 hydrochloride |
Apoptosis; Acyltransferase | Apoptosis; Metabolism |
Nevanimibe hydrochloride (PD-132301 hydrochloride) 是一种口服有效的,选择性酰基辅酶 A:胆固醇 O-酰基转移酶 1 抑制剂,EC50为 9 nM。它抑制 ACAT2,EC50为 368 nM。它诱导细胞凋亡,具有抗肾上腺皮质癌的潜力。 | |||
T11733 |
K-604 dihydrochloride
|
Acyltransferase | Metabolism |
K-604 dihydrochloride 是酰基辅酶 A:胆固醇酰基转移酶 1 的选择性抑制剂,IC50为 0.45±0.06 μM。 | |||
T62974 |
Pactimibe sulfate
|
||
Pactimibe sulfate (CS-505) 是一种双重的 ACAT1/2 抑制剂,能够作用于 ACAT1 (IC50: 4.9 μM)、ACAT2 (IC50: 3.0 μM)。Pactimibe sulfate 对 ACAT 表现出抑制作用,在肝细胞中 IC50=2.0 μM,在巨噬细胞中 IC50=2.7 μM,在 THP-1 细胞中 IC50=4.7 μM。Pactimibe sulfate 能够非竞争性地抑制 oleoyl-CoA (Ki: 5.6 μM),显著抑制胆固醇酯的形成 (IC50: 6.7 μM)。Pactimibe sulfate 能够降低血浆胆固醇的活性,具有抗动脉粥样硬化的潜力。 | |||
T12225 |
Nevanimibe
ATR-101,PD-132301 |
Others | Others |
Nevanimibe is an orally active and selective inhibitor of acyl-coenzyme A:cholesterol O-acyltransferase 1 (ACAT1) (EC50 of 9 nM). | |||
T28290 |
Pactimibe
CS 505,CS-505,CS505,Pactimibe free base,帕替麦布 |
||
Pactimibe is a ACAT inhibitor. It has anti-atherosclerotic activity. |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T12592 |
Pyripyropene A
|
Others | Others |
Pyripyropene A is a potent and selective inhibitor of sterol O-acyltransferase 2 (SOAT2)/acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2)(IC50 of 0.07 µM). |